160 Health International Limited于2026年7月17日向香港交易所提交Next Day Disclosure Return，披露因行使Pre-IPO股份期权计划而产生的股本变动。
截至2026年6月30日，公司已发行普通股336.45 million股。本次在2026年7月17日按Pre-IPO股份期权计划（2023年8月31日获批及采纳）配发及发行10.79 million股，增幅占增发前已发行股本的3.21%。发行价为每股USD 0.000002。
完成后，公司总已发行股本增至347.24 million股；期末未持有任何库藏股，亦无股份回购或注销事项。
文件由董事会主席、执行董事兼首席执行官罗宁铮签署，并确认本次股份发行已获得董事会授权，符合香港联交所上市规则及相关法律法规的要求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.